PL1789053T3 - Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B - Google Patents

Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B

Info

Publication number
PL1789053T3
PL1789053T3 PL05811901T PL05811901T PL1789053T3 PL 1789053 T3 PL1789053 T3 PL 1789053T3 PL 05811901 T PL05811901 T PL 05811901T PL 05811901 T PL05811901 T PL 05811901T PL 1789053 T3 PL1789053 T3 PL 1789053T3
Authority
PL
Poland
Prior art keywords
wound healing
receptor antagonists
adenosine receptor
adenosine
antagonists
Prior art date
Application number
PL05811901T
Other languages
English (en)
Inventor
Dewan Zeng
Luiz Belardinelli
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL1789053T3 publication Critical patent/PL1789053T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PL05811901T 2004-09-01 2005-08-30 Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B PL1789053T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists
EP05811901A EP1789053B1 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
PL1789053T3 true PL1789053T3 (pl) 2012-12-31

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05811901T PL1789053T3 (pl) 2004-09-01 2005-08-30 Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B

Country Status (21)

Country Link
US (1) US20060058322A1 (pl)
EP (1) EP1789053B1 (pl)
JP (2) JP4929173B2 (pl)
KR (1) KR101247528B1 (pl)
CN (1) CN101043889B (pl)
AU (1) AU2005282860B2 (pl)
CA (1) CA2578702A1 (pl)
DK (1) DK1789053T3 (pl)
ES (1) ES2387653T3 (pl)
HR (1) HRP20120712T1 (pl)
IL (1) IL181634A (pl)
MX (1) MX2007002437A (pl)
NO (1) NO20071718L (pl)
NZ (1) NZ553487A (pl)
PL (1) PL1789053T3 (pl)
PT (1) PT1789053E (pl)
RS (1) RS52455B (pl)
RU (1) RU2385322C2 (pl)
SI (1) SI1789053T1 (pl)
WO (1) WO2006028810A2 (pl)
ZA (1) ZA200701777B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658291B1 (en) 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
JP7849948B2 (ja) * 2018-03-05 2026-04-22 テオン セラピューティクス，インク． アデノシン受容体アンタゴニストおよびその使用
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
EP4211135A1 (en) * 2020-09-04 2023-07-19 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6894021B2 (en) * 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists

Also Published As

Publication number Publication date
CN101043889A (zh) 2007-09-26
IL181634A (en) 2015-05-31
JP2011246492A (ja) 2011-12-08
JP4929173B2 (ja) 2012-05-09
PT1789053E (pt) 2012-08-09
ES2387653T3 (es) 2012-09-27
WO2006028810A3 (en) 2006-09-28
US20060058322A1 (en) 2006-03-16
WO2006028810A2 (en) 2006-03-16
RU2385322C2 (ru) 2010-03-27
DK1789053T3 (da) 2012-08-06
HK1107261A1 (en) 2008-04-03
CN101043889B (zh) 2010-11-03
NZ553487A (en) 2010-09-30
AU2005282860B2 (en) 2012-03-22
RU2007107605A (ru) 2008-09-10
KR101247528B1 (ko) 2013-04-15
MX2007002437A (es) 2007-08-14
HRP20120712T1 (hr) 2012-10-31
CA2578702A1 (en) 2006-03-16
RS52455B (sr) 2013-02-28
KR20070047816A (ko) 2007-05-07
AU2005282860A1 (en) 2006-03-16
EP1789053B1 (en) 2012-06-13
EP1789053A2 (en) 2007-05-30
ZA200701777B (en) 2008-09-25
NO20071718L (no) 2007-03-30
JP2008511654A (ja) 2008-04-17
IL181634A0 (en) 2007-07-04
SI1789053T1 (sl) 2012-09-28

Similar Documents

Publication Publication Date Title
ZA200701777B (en) Method of wound healing using A2B adenosine receptor antagonists
IL178365A (en) Selective antagonists of a2a adenosine receptors
IL182493A0 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
TWI365879B (en) A2b adenosine receptor antagonists
ZA200703229B (en) Use of A2A adenosine receptor agonists
IL188103A0 (en) Prodrugs of a2b adenosine receptor antagonists
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
IL196536A0 (en) Selective antagonists of a2a adenosine receptors
ZA200903574B (en) 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
IL176879A0 (en) Hydroisoindoline tachykinin receptor antagonists
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
PL1786744T3 (pl) Sposób opóźniania wiązania gipsu i preparatów gipsowych
PL1751175T3 (pl) Antagoniści receptora IL-1, kompozycje i sposoby leczenia
GB0411123D0 (en) High-affinity NY-ESO T cell receptors
EP1773367A4 (en) RECEPTOR ANTAGONISTS FOR EPIDERMAL GROWTH FACTOR AND USE METHOD
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
ZA200707714B (en) Highly potent full and partial agonists and antagonists of the nociceptin/orphanin FQ receptor
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
HK1099015A (en) Selective antagonists of a2a adenosine receptors
GB0622684D0 (en) Feed preparation device and method of use
PL383615A1 (pl) Arylindenopirydyny i arylindenopirymidyny oraz ich zastosowanie jako antagonistów receptora adenozynowego A2a
IL182420A0 (en) Crf receptor antagonists and methods relating thereto
HK1109728A (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
ZA200608369B (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists